{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:06:40Z","timestamp":1783181200955,"version":"3.54.6"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["Italian National Funding for Centers of Excellence (Science Department, Roma Tre University\u2014MIUR, Articolo 1, Commi 314\u2013337 Legge 232\/2016)."],"award-info":[{"award-number":["Italian National Funding for Centers of Excellence (Science Department, Roma Tre University\u2014MIUR, Articolo 1, Commi 314\u2013337 Legge 232\/2016)."]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["Italian National Funding for Centers of Excellence (Science Department, Roma Tre University\u2014MIUR, Articolo 1, Commi 314\u2013337 Legge 232\/2016)."],"award-info":[{"award-number":["Italian National Funding for Centers of Excellence (Science Department, Roma Tre University\u2014MIUR, Articolo 1, Commi 314\u2013337 Legge 232\/2016)."]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>COVID-19 is the global pandemic that affected our population in the past 2 years. Considerable research has been done to better understand the pathophysiology of this disease and to identify new therapeutic targets, especially for severe cases. Galectin-3 (Gal-3) is a receptor present at the surface of different cell types, namely epithelial and inflammatory cells, which has been described as a severity marker in COVID-19. The activation of Gal-3 through its binding protein (Gal-3BP) is directly linked to the production of pro-inflammatory cytokines that contribute for the cytokine storm (CS) observed in severe COVID-19 patients. Here, we show that D2, a recombinant fragment of the lectin-binding region of Gal-3BP was able to stimulate the expression of IL-6 in colon and lung epithelial cell lines in \u03b2-galactoside dependent manner. We further show that D2-induced IL-6 augmentation was reduced by the anti-Gal-3BP monoclonal antibody 1959. Our data confirm and extend prior findings of Gal-3BP mediated IL-6 induction, enlightening the potential of its antibody-mediated s blockage for the prevention and treatment of\u00a0CS and severe disease in COVID-19 patients.<\/jats:p>","DOI":"10.1038\/s41598-022-20852-x","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T17:06:01Z","timestamp":1665507961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Galectin-3 binding protein stimulated IL-6 expression is impeded by antibody intervention in SARS-CoV-2 susceptible cell lines"],"prefix":"10.1038","volume":"12","author":[{"given":"Ana","family":"Mendes-Frias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Iacobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Iacobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"20852_CR1","unstructured":"COVID Live: Coronavirus Statistics\u2014Worldometer. https:\/\/www.worldometers.info\/coronavirus\/. Accessed 7 March 7 2022."},{"key":"20852_CR2","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1007\/s00134-020-06140-0","volume":"46","author":"M Cecconi","year":"2020","unstructured":"Cecconi, M., Forni, G. & Mantovani, A. Ten things we learned about COVID-19. Intensive Care Med. 46, 1590\u20131593. https:\/\/doi.org\/10.1007\/s00134-020-06140-0 (2020).","journal-title":"Intensive Care Med."},{"key":"20852_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cytogfr.2020.05.003","volume":"53","author":"F Coperchini","year":"2020","unstructured":"Coperchini, F., Chiovato, L., Croce, L., Magri, F. & Rotondi, M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine\/chemokine-receptor system. Cytokine Growth Factor Rev. 53, 25\u201332. https:\/\/doi.org\/10.1016\/j.cytogfr.2020.05.003 (2020).","journal-title":"Cytokine Growth Factor Rev."},{"key":"20852_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13662-021-03317-9","volume":"1","author":"T Omay","year":"2021","unstructured":"Omay, T. & Baleanu, D. Fractional unit-root tests allowing for a fractional frequency flexible Fourier form trend: Predictability of Covid-19. Adv. Differ. Equ. 1, 167. https:\/\/doi.org\/10.1186\/s13662-021-03317-9 (2021).","journal-title":"Adv. Differ. Equ."},{"key":"20852_CR5","doi-asserted-by":"publisher","first-page":"101019","DOI":"10.1016\/j.nantod.2020.101019","volume":"36","author":"Z Tang","year":"2021","unstructured":"Tang, Z. et al. Insights from nanotechnology in COVID-19 treatment. Nano Today 36, 101019. https:\/\/doi.org\/10.1016\/j.nantod.2020.101019 (2021).","journal-title":"Nano Today"},{"key":"20852_CR6","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.2c00123","author":"N Mahmud","year":"2022","unstructured":"Mahmud, N. et al. Advances in nanomaterial-based platforms to combat COVID-19: Diagnostics, preventions, therapeutics, and vaccine developments. ACS Appl. Bio Mater. https:\/\/doi.org\/10.1021\/acsabm.2c00123 (2022).","journal-title":"ACS Appl. Bio Mater."},{"key":"20852_CR7","doi-asserted-by":"publisher","first-page":"101243","DOI":"10.1016\/j.nantod.2021.101243","volume":"40","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. TiO2 supported single Ag atoms nanozyme for elimination of SARS-CoV2. Nano Today 40, 101243. https:\/\/doi.org\/10.1016\/j.nantod.2021.101243 (2021).","journal-title":"Nano Today"},{"issue":"9","key":"20852_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41377-020-00388-3","volume":"15","author":"Z Xie","year":"2020","unstructured":"Xie, Z. et al. Black phosphorus-based photothermal therapy with aCD47-mediated immune checkpoint blockade for enhanced cancer immunotherapy. Light Sci. Appl. 15(9), 161. https:\/\/doi.org\/10.1038\/s41377-020-00388-3 (2020).","journal-title":"Light Sci. Appl."},{"issue":"15","key":"20852_CR9","doi-asserted-by":"publisher","first-page":"eaay6825","DOI":"10.1126\/sciadv.aay6825","volume":"6","author":"S Chen","year":"2020","unstructured":"Chen, S. et al. Eradication of tumor growth by delivering novel photothermal selenium-coated tellurium nanoheterojunctions. Sci. Adv. 6(15), eaay6825. https:\/\/doi.org\/10.1126\/sciadv.aay6825 (2020).","journal-title":"Sci. Adv."},{"key":"20852_CR10","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1039\/c7tb01068k","volume":"5","author":"F Yin","year":"2017","unstructured":"Yin, F. et al. Black phosphorus quantum dot based novel siRNA delivery systems in human pluripotent teratoma PA-1 cells. J. Mater. Chem. B 5, 5433\u20135440. https:\/\/doi.org\/10.1039\/c7tb01068k (2017).","journal-title":"J. Mater. Chem. B"},{"issue":"4","key":"20852_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 8(4), 420\u2013422. https:\/\/doi.org\/10.1016\/S2213-2600(20)30076-X (2020).","journal-title":"Lancet Respir. Med."},{"key":"20852_CR12","doi-asserted-by":"publisher","first-page":"108536","DOI":"10.1016\/j.intimp.2022.108536","volume":"105","author":"R Elahi","year":"2022","unstructured":"Elahi, R., Karami, P., Heidary, A. H. & Esmaeilzadeh, A. An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19). Int. Immunopharmacol. 105, 108536. https:\/\/doi.org\/10.1016\/j.intimp.2022.108536 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"20852_CR13","first-page":"3005","volume":"46","author":"S Iacobelli","year":"1986","unstructured":"Iacobelli, S., Arn\u00f2, E., D\u2019orazio, A. & Coletti, G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 46, 3005\u20133010 (1986).","journal-title":"Cancer Res."},{"key":"20852_CR14","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1021\/bi00358a037","volume":"25","author":"PS Linsley","year":"2002","unstructured":"Linsley, P. S. et al. Identification of a novel serum protein secreted by lung carcinoma cells. Biochemistry 25, 2978\u20132986. https:\/\/doi.org\/10.1021\/bi00358a037 (1986).","journal-title":"Biochemistry"},{"key":"20852_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/S12967-021-03085-W","author":"E Capone","year":"2021","unstructured":"Capone, E., Iacobelli, S. & Sala, G. Role of galectin 3 binding protein in cancer progression: A potential novel therapeutic target. J. Transl. Med. https:\/\/doi.org\/10.1186\/S12967-021-03085-W (2021).","journal-title":"J. Transl. Med."},{"key":"20852_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1023\/B:GLYC.0000014085.00706.d4","volume":"19","author":"A Grassadonia","year":"2002","unstructured":"Grassadonia, A. et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj. J. 19, 551\u2013556. https:\/\/doi.org\/10.1023\/B:GLYC.0000014085.00706.d4 (2002).","journal-title":"Glycoconj. J."},{"key":"20852_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/infdis\/164.4.819","volume":"164","author":"S Iacobelli","year":"1991","unstructured":"Iacobelli, S. et al. Lipoprotein 90K in human immunodeficiency virus-infected patients: A further serologic marker of progression. J. Infect. Dis. 164, 819.\u00a0https:\/\/doi.org\/10.1093\/infdis\/164.4.819 (1991).","journal-title":"J. Infect. Dis."},{"key":"20852_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/infdis\/164.3.616","volume":"164","author":"C Natoli","year":"1991","unstructured":"Natoli, C., Iacobelli, S. & Ghinelli, F. Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. J. Infect. Dis. 164, 616\u2013617. https:\/\/doi.org\/10.1093\/infdis\/164.3.616 (1991).","journal-title":"J. Infect. Dis."},{"key":"20852_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/s0168-8278(96)80076-6","volume":"25","author":"M Artini","year":"1996","unstructured":"Artini, M. et al. Elevated serum levels of 90K\/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J. Hepatol. 25, 212\u2013217. https:\/\/doi.org\/10.1016\/s0168-8278(96)80076-6 (1996).","journal-title":"J. Hepatol."},{"key":"20852_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-021-00788-8","author":"V Gallo","year":"2022","unstructured":"Gallo, V. et al. Increased Gal-3BP plasma levels in hospitalized patients infected with SARS-CoV-2. Clin. Exp. Med. https:\/\/doi.org\/10.1007\/s10238-021-00788-8 (2022).","journal-title":"Clin. Exp. Med."},{"key":"20852_CR21","doi-asserted-by":"publisher","first-page":"18573","DOI":"10.1074\/jbc.M803115200","volume":"283","author":"Y Fukaya","year":"2008","unstructured":"Fukaya, Y., Shimada, H., Wang, L. C., Zandi, E. & DeClerck, Y. A. Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J. Biol. Chem. 283, 18573\u201318581. https:\/\/doi.org\/10.1074\/jbc.M803115200 (2008).","journal-title":"J. Biol. Chem."},{"key":"20852_CR22","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1158\/0008-5472.CAN-11-2165","volume":"72","author":"AM Silverman","year":"2012","unstructured":"Silverman, A. M., Nakata, R., Shimada, H., Sposto, R. & DeClerck, Y. A. A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma. Can. Res. 72, 2228\u20132238. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2165 (2012).","journal-title":"Can. Res."},{"key":"20852_CR23","doi-asserted-by":"publisher","first-page":"18401","DOI":"10.1016\/S0021-9258(17)32322-0","volume":"269","author":"A Ullrich","year":"1994","unstructured":"Ullrich, A. et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. J. Biol. Chem. 269, 18401\u201318407 (1994).","journal-title":"J. Biol. Chem."},{"key":"20852_CR24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/JLB.3VMR0118-036R","volume":"104","author":"V Loimaranta","year":"2018","unstructured":"Loimaranta, V., Hepojoki, J., Laaksoaho, O. & Pulliainen, A. T. Galectin-3-binding protein: A multitask glycoprotein with innate immunity functions in viral and bacterial infections. J. Leukoc. Biol. 104, 777\u2013786. https:\/\/doi.org\/10.1002\/JLB.3VMR0118-036R (2018).","journal-title":"J. Leukoc. Biol."},{"key":"20852_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/FPHYS.2018.01247","author":"J Gaifem","year":"2018","unstructured":"Gaifem, J. et al. L-Threonine supplementation during colitis onset delays disease recovery. Front. Physiol. https:\/\/doi.org\/10.3389\/FPHYS.2018.01247 (2018).","journal-title":"Front. Physiol."},{"key":"20852_CR26","first-page":"4530","volume":"56","author":"H Inohara","year":"1996","unstructured":"Inohara, H. et al. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res. 56, 4530\u20134534 (1996).","journal-title":"Cancer Res."},{"key":"20852_CR27","doi-asserted-by":"publisher","first-page":"668507","DOI":"10.3389\/fimmu.2021.668507","volume":"12","author":"F Coperchini","year":"2021","unstructured":"Coperchini, F., Chiovato, L. & Rotondi, M. Interleukin-6, CXCL10 and infiltrating macrophages in COVID-19-related cytokine storm: Not one for all but all for one!. Front. Immunol. 12, 668507. https:\/\/doi.org\/10.3389\/fimmu.2021.668507 (2021).","journal-title":"Front. Immunol."},{"issue":"1","key":"20852_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cels.2020.05.012","volume":"11","author":"CB Messner","year":"2020","unstructured":"Messner, C. B. et al. Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Syst. 11(1), 11-24.e4. https:\/\/doi.org\/10.1016\/j.cels.2020.05.012 (2020).","journal-title":"Cell Syst."},{"issue":"1","key":"20852_CR29","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1038\/s41467-021-23494-1","volume":"12","author":"C Gutmann","year":"2021","unstructured":"Gutmann, C. et al. SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. Nat. Commun. 12(1), 3406. https:\/\/doi.org\/10.1038\/s41467-021-23494-1 (2021).","journal-title":"Nat. Commun."},{"key":"20852_CR30","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10719-021-10021-z","volume":"38","author":"I Trbojevi\u0107-Akma\u010di\u0107","year":"2021","unstructured":"Trbojevi\u0107-Akma\u010di\u0107, I., Petrovi\u0107, T. & Lauc, G. SARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infection. Glycoconj. J. 38, 611\u2013623. https:\/\/doi.org\/10.1007\/s10719-021-10021-z (2021).","journal-title":"Glycoconj. J."},{"key":"20852_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/J.RMED.2021.106556","author":"A Portacci","year":"2021","unstructured":"Portacci, A. et al. Galectin-3 as prognostic biomarker in patients with COVID-19 acute respiratory failure. Respir. Med. https:\/\/doi.org\/10.1016\/J.RMED.2021.106556 (2021).","journal-title":"Respir. Med."},{"key":"20852_CR32","doi-asserted-by":"publisher","first-page":"e9392","DOI":"10.7717\/peerj.9392","volume":"8","author":"JL Caniglia","year":"2020","unstructured":"Caniglia, J. L., Guda, M. R., Asuthkar, S., Tsung, A. J. & Velpula, K. K. A potential role for Galectin-3 inhibitors in the treatment of COVID-19. PeerJ 8, e9392. https:\/\/doi.org\/10.7717\/peerj.9392 (2020).","journal-title":"PeerJ"},{"issue":"13","key":"20852_CR33","doi-asserted-by":"publisher","first-page":"7314","DOI":"10.3390\/ijms23137314","volume":"23","author":"V Gallo","year":"2022","unstructured":"Gallo, V., Arienzo, A., Iacobelli, S., Iacobelli, V. & Antonini, G. Gal-3BP in viral infections: An emerging role in severe acute respiratory syndrome coronavirus 2. Int. J. Mol. Sci. 23(13), 7314. https:\/\/doi.org\/10.3390\/ijms23137314 (2022).","journal-title":"Int. J. Mol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20852-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20852-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20852-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T17:10:13Z","timestamp":1665508213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20852-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["20852"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-20852-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"assertion":[{"value":"16 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17047"}}